← Back to headlines
Bayer Receives FDA Priority Review for Asundexian
Bayer has been granted FDA priority review for its drug asundexian, intended for use in stroke and TIA patients.
19 May, 06:41 — 19 May, 06:41
Sources
Showing 1 of 1 sources
Bayer has been granted FDA priority review for its drug asundexian, intended for use in stroke and TIA patients.
